Mylan has appointed John Montgomery as the new president of Asia Pacific operations following the completion of Mylan's acquisition of Merck Generics Group.
Subscribe to our email newsletter
Mr Montgomery has worked for over 30 years in the pharmaceuticals industry and has extensive experience in both patented and generics pharmaceutical products in the UK, US and Asia Pacific regions. At Merck Generics, he served as regional director, Asia Pacific, and CEO of Alphapharm, Merck Generics’s business in Australia.
Robert Coury, vice chairman and CEO of Mylan, commented: “I have seen first hand that John is a truly skilled leader with the vision that makes him a perfect fit for Mylan. He brings an impressive track record and true depth of experience to our senior team. Asia Pacific is an important region with an attractive growth profile, particularly in Japan.
“Under John’s leadership, his business ranks number one in both Australia and New Zealand, and also ranks as the leading multinational generics company in Japan. I am confident that we are extremely well-placed to leverage the many opportunities we see in the region from our position as a new global leader in the generics and specialty pharmaceutical industry.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.